Reviewing its MedTech coverage ahead of the Q2 earnings season on Tuesday, Morgan Stanley upgraded Steris (NYSE:STE) and Solventum (NYSE:SOLV) to Overweight from Equal Weight and downgraded RxSight (NASDAQ:RXST) to Equal Weight from Overweight.

Analyst Patrick Wood welcomed the industry